Get the Stockscreener App
0.00
100.00%
-3.65
After Hours:
3.66
3.66
+
Revance Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$3.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$381.02M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
0.00
EPS:
-3.8
Net Cash Flow:
$-223.46M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.65
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Compare RVNC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 381.02M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | Mizuho | Buy → Neutral |
| Jan-09-24 | Downgrade | Goldman | Buy → Neutral |
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
JPMorgan Chase & Co. Sells 2,335,359 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Reduces Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Wellington Management Group LLP Trims Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Norges Bank Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
KLP Kapitalforvaltning AS Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Commonwealth Equity Services LLC Cuts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts - Defense World
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - Defense World
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco - The Malaysian Reserve
Public market insider buying at Prime Mining (PRYM) - The Globe and Mail
RVNC INVESTIGATION: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - ACCESS Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022RVNC - ACCESS Newswire
Crown Laboratories rebrands as Revance following acquisition - MSN
Johnson City-based Crown Labs now operating as ‘Revance’ - WJHL
Crown Laboratories Now Operates Under the Name Revance - PR Newswire
Charles Schwab Investment Management Inc. Grows Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Purchased by Charles Schwab Investment Management Inc. - The AM Reporter
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Bank of New York Mellon Corp Sells 18,519 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC - Business Wire
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm - Louisiana First News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Average Price Target from Brokerages - Defense World
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com - Defense World
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - Defense World
Rhumbline Advisers Boosts Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
ForexTV | Small Business Resources - ForexTV.com
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC) - Stockhouse Publishing
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025RVNC - ACCESS Newswire
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, - GlobeNewswire
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Revance Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
2025-03-03 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-03-02 | Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | Press Release - Stockhouse Publishing
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - Defense World
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025- RVNC - ACCESS Newswire
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):